B. Riley Financial reissued a "buy" rating and set a $17.00 price objective (down from $23.00) on shares of Anika Therapeutics in a research note on Monday...
B. Riley Financial reissued a "buy" rating and set a $17.00 price objective (down from $23.00) on shares of Anika Therapeutics in a research note on Monday...
Anika (ANIK) delivered earnings and revenue surprises of +70.59% and +3.94%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?
Regenxbio (RGNX) delivered earnings and revenue surprises of +54.07% and -4.53%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?
Puma Biotechnology starts the ALISCA-Lung2 phase II study evaluating alisertib in combination with paclitaxel in patients with advanced small cell lung cancer.
Rocket Pharmaceuticals aligns with the FDA on key phase II study elements for RP-A501, advancing its Danon disease gene therapy program toward completion.